Pfizer says U.S. court invalidates Celebrex patent; generics loom — Reuters
Pfizer — U.S. court invalidates Celebrex patent; generics loom | Reuters: Ouch!:-( Knocking the block of of the buster. Pfizer is taking a big hit with this court ruling against Celebrex patent. Surprisingly, the stock price, not so much so. Almost not even a jitter as it stays around $32 per share. That’s $3B in annual sales with $2B in the US (relevant to the US court ruling, obviously). IF the company repeats its $51B…